IDEAYA Announces First Patient Dosing of IDE196 for Solid Tumors outside of Uveal Melanoma and a Collaboration with Foundation Medicine in support of its Tumor-Agnostic GNAQ/11 Basket Trial

By In The News
October 8, 2019 in The Headlines

Recommended Posts

In The News

Posted October 8, 2019

- Share

Posted October 8, 2019

SOUTH SAN FRANCISCO, Oct. 8, 2019 /PRNewswire/ -- IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announces it has dosed its first patient with cutaneous melanoma harboring a GNAQ...

View the full article

Link to comment

Share on other sites

Archived

This topic is now archived and is closed to further replies.

Go to topic listing

Most Contributions
1. In The News
  215437
2. Jaydee
  15233
3. Kip Powick
  11957
4. deicer
  11241
5. dagger
  9578
Tell a friend
Love The Airline Website? Tell a friend!
- Email
- Share
Forum Statistics
- Total Topics
  
  265.7k
- Total Posts
  
  549.3k

Sign In

IDEAYA Announces First Patient Dosing of IDE196 for Solid Tumors outside of Uveal Melanoma and a Collaboration with Foundation Medicine in support of its Tumor-Agnostic GNAQ/11 Basket Trial

Recommended Posts

In The News

Link to comment

Share on other sites

Archived

Most Contributions

Tell a friend

Forum Statistics

Browse

Activity

Support